Respiratory diseases

Upstream Bio (UPB) presented data at the European Respiratory Society Congress showcasing verekitug’s mechanism of action. Verekitug prevents TSLP binding by occupying receptor sites and outcompetes TSLP even with preformed receptor complexes. This supports its potential for treating TSLP-driven respiratory diseases. Phase 2 data in CRSwNP showed significant improvements. A Phase 2 readout in severe asthma is expected in Q1 2026. Verekitug’s high affinity and inhibition of the TSLP receptor could lead to less frequent dosing than current therapies.